Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
about
Dopamine agonists for hyperprolactinaemiaTreatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A ReviewThe risks of overlooking the diagnosis of secreting pituitary adenomasGamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results.Pituitary incidentaloma: an endocrine society clinical practice guideline.Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.Hyperprolactinaemia - a problem in patients from the reproductive period to the menopause.Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach.Lactation associated with a pituitary tumour in a man.The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor ShrinkageManagement of macroprolactinomas.Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.Combined high-field intraoperative magnetic resonance imaging and endoscopy increase extent of resection and progression-free survival for pituitary adenomas.Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin.New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literatureEarly prediction of long-term response to cabergoline in patients with macroprolactinomasErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic miceHER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.Characteristics of dynamic magnetic resonance image enhancement in prolactinomas resistant to dopamine agonist therapy.Treatment of prolactinomas in low-income countries.Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia.Endocrinological outcomes of pure endoscopic transsphenoidal surgery: a Croatian Referral Pituitary Center experienceEffect of dopaminergic drug treatment on surgical findings in prolactinomas.Ultrafiltration - an alternative method to polyethylene glycol precipitation for macroprolactin detection.A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case reportTreatment of hyperprolactinemia: a systematic review and meta-analysis.The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas.Establishing reference intervals for sex hormones on the analytical platforms Advia Centaur and Immulite 2000XP.A novel surgical approach for the management of giant invasive prolactinoma compressing the brainstemSuppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.Diagnostic Accuracy of Perioperative Measurement of Basal Anterior Pituitary and Target Gland Hormones in Predicting Adrenal Insufficiency After Pituitary SurgeryRat prolactinoma cell growth regulation by epidermal growth factor receptor ligandsEffects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery.A unique case of Turner syndrome accompanying prolactinoma and unexpected elongated styloid process: Clinical and cone-beam computed tomographic featuresPregnancy in multiple endocrine neoplasia type 1 equals multiple complicationsAripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital.Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.Heregulin regulates prolactinoma gene expression.Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy
P2860
Q24201524-CD64026E-F452-415A-8170-21839C70A110Q26739267-6C134663-7085-4D3C-9789-3A7045CB6748Q28076665-3545A053-BD6A-46F4-99F9-0809613C50ACQ30299965-8DEA7626-7F87-4C27-BA80-DC0D70C3487EQ30353104-9B1C457A-F2C3-4309-BC00-5DC24C38D404Q33680681-9C76F892-17B8-41C5-BFC1-832D71D886F9Q33704842-2D0A6BBD-036A-434E-A88A-9207A43D6CDFQ33721266-19D73DD3-56E4-4FFB-A8AE-E7680D1623C7Q33753848-44F1EA05-CBA7-4022-839F-611F975BCEEDQ33770763-7A993A8D-40B1-448F-81D6-BEB93E8DFE70Q33792371-4342DC07-460E-4F83-B32C-E7560737F7CDQ33943570-49BD45D2-07D2-4ADE-AD47-27E2316AD473Q34167819-67335044-38BD-4957-AC70-2761B834483CQ34211804-5576CC5F-6BBB-4095-ADDE-DF1F890D3D18Q34296291-3C02B340-4014-4FE8-AB4F-7C2735EEC73CQ34318860-5D30B9FC-1FA5-470F-82C4-B180A5595452Q34745279-4EE5447F-B20E-4DA8-A41A-BD30DCF32432Q34942996-B2CB7C89-2D94-4AD2-B5E7-86CCCDC6FFF5Q35106933-55C8AA25-0BF5-4F55-ADC5-1BE4941DEF14Q35109902-E5D42C06-519E-4981-8DFA-59F2601B244CQ35137687-7C5D7AF6-AF69-493C-9A17-F954D5572A01Q35589236-EA833296-1D79-42E4-A1EF-72DEF83FFA98Q36011347-2A7DE7C9-9967-4FE6-A60E-74E799DB8C2FQ36182003-543E8C77-A461-4568-B1FE-25E79252BA21Q36220645-E4563A8F-E281-4BF1-8E70-250D5E0BA82FQ36322256-69608169-D4BA-4068-A61D-BB56BB199EA3Q36355322-B49407C8-65F4-453C-8924-66CC47037BDAQ36412084-1D78200F-DC5F-4C0D-B0F5-CBABF4E61312Q36419694-63DA5ECE-D0D1-4D8B-8445-99ABCDB79EE0Q36427494-14782AAB-92B9-4D75-8E3C-CF2F9041DC94Q36629594-465ABF66-FE9C-48E2-9C41-DABBAA82BC9BQ36663948-C548CDE4-BA7B-4C9C-8C20-6FF984A23F79Q36813498-E1561AFC-A5AB-490A-BAEB-56B24DB85FCBQ36824494-D75CAF6C-A1C8-4D35-85BF-281CF3B6E9F9Q36951783-1B3A8B0A-AD70-4F21-AB8C-0C6C0E5AE539Q37070365-91AC8E86-3A85-4686-B9C0-DA4B60A716DFQ37078928-6C46B9FA-BCA0-42B3-B5CD-DA0B1E0E81C9Q37162791-64C2D445-E4C2-4759-B36F-BDF1AEE3C277Q37208143-BEC36AAB-CF62-4695-BD47-C0C843DF1043Q37257610-948C21B4-4A69-4B8F-8BFB-918CD69AC1BA
P2860
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
@en
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
@nl
type
label
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
@en
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
@nl
prefLabel
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
@en
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
@nl
P2093
P2860
P50
P1476
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
@en
P2093
Andrea Giustina
David Kleinberg
Edward Laws
Felipe F Casanueva
Hugo Fideleff
John A H Wass
Luis G Sobrinho
Marcello D Bronstein
Mark E Molitch
Maurice Scanlon
P2860
P304
P356
10.1111/J.1365-2265.2006.02562.X
P577
2006-08-01T00:00:00Z